Piramal acquires blood plasma range from PlasmaSelect
This article was originally published in Scrip
Executive Summary
Piramal Healthcareof India has completed a definitive agreement with PlasmaSelect of Germany to acquire PlasmaSelect’s polygeline-based blood plasma products (marketed as Haemaccel) for €7.7 million. Piramal Healthcare (previously Nicholas Piramal) expects to build a leadership position in polygeline-based blood plasma expansion products through the acquisition.